InspireMD, Inc. (NSPR) News
Follow InspireMD, Inc. (NSPR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
InspireMD lowers warrant exercise price to $0.7674
InspireMD amended certain Series J and Series K warrant terms, setting the exercise price to $0.7674 for 50% of shares under amending Series J warrants and for all shares under amending Series K warrants.
EQUITY | Sep 21, 2026, 01:14 PM UTC
L
NSPR - InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
NSPR - InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
NEWS | Sep 21, 2026, 01:00 PM UTC
H
Full Transcript: InspireMD Q2 2026 Earnings Call
InspireMD (NASDAQ: NSPR ) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-time
LIVE | Sep 17, 2026, 09:42 AM UTC
L
NSPR: Innovative carotid stent technology is set to disrupt a rapidly expanding U.S. vascular market
A novel carotid stent with a 20-micron mesh is driving superior clinical outcomes and rapid adoption in a $1 billion U.S. market, supported by strong trial results, recent CMS reimbursement, and robust funding. Regulator
NEWS | Sep 14, 2026, 10:26 PM UTC
L
NSPR: Innovative carotid stent technology is set to transform stroke prevention and capture U.S. market share
A novel carotid stent with a 20-micron mesh is driving best-in-class outcomes and rapid adoption in a $1B U.S. market, supported by strong clinical evidence, recent CMS reimbursement, and robust funding. TCAR and CAS mar
REGULATION | Sep 14, 2026, 10:19 PM UTC
L
InspireMD board compensation committee approves inducement grants
InspireMD said its Board of Directors’ Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:07 PM UTC
L
NSPR/InspireMD announces inducement grants under Nasdaq Rule 5635(c)(4)
InspireMD announced inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 08:01 PM UTC
L
InspireMD plans conference presentation at H.C. Wainwright event Monday
InspireMD said it plans to present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday.
EQUITY | Sep 03, 2026, 12:08 PM UTC
L
NSPR - InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
NSPR - InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
EQUITY | Sep 03, 2026, 12:00 PM UTC
L
InspireMD (NSPR) reports second-quarter 2026 financial results
InspireMD (NSPR) reports its second-quarter 2026 financial results, according to TradeXchange Newsdesk, with no additional figures or catalysts provided in the source text.
EARNINGS | Aug 17, 2026, 11:00 AM UTC
M
NSPR Appoints Kathleen Kennedy
NSPR appoints new sales and marketing leader
EQUITY | Jul 30, 2026, 08:01 PM UTC